Phase I single ascending dose and food effect study in healthy adults and phase I/IIa multiple...

M Hoelscher, D Barros-Aguirre, M Dara… - Clinical Microbiology …, 2024 - Elsevier

Background Tuberculosis (TB) is the leading cause of mortality by an infectious disease
world-wide. Despite national and international efforts, the world is not on track to end TB by …

Non-tuberculous mycobacterial disease: progress and advances in the development of novel candidate and repurposed drugs

Y Gu, W Nie, H Huang, X Yu - Frontiers in Cellular and Infection …, 2023 - frontiersin.org

Non-tuberculous mycobacteria (NTM) are opportunistic pathogens that can infect all body
tissues and organs. In particular, the lungs are the most commonly involved organ, with NTM …

被引用次数：2 相关文章所有 6 个版本

Restocking the tuberculosis drug arsenal

EL Nuermberger, RE Chaisson - Nature medicine, 2024 - nature.com

Restocking the tuberculosis drug arsenal | Nature Medicine Skip to main content Thank you for
visiting nature.com. You are using a browser version with limited support for CSS. To obtain the …

被引用次数：1 相关文章所有 4 个版本

[PDF] springer.com

Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c …

R Dawson, AH Diacon, S Takuva, Y Liu, B Zheng… - Trials, 2024 - Springer

Background Delamanid and bedaquiline are two of the most recently developed
antituberculosis (TB) drugs that have been extensively studied in patients with multidrug …

[PDF][PDF] Rodney Dawson1, Andreas H. Diacon2, 3, Simbarashe Takuva4, 5, Yongge Liu6, Bo Zheng6, Vatsala Karwe6 and

J Hafkin - 2024 - trialsjournal.biomedcentral.com

Background Delamanid and bedaquiline are two of the most recently developed
antituberculosis (TB) drugs that have been extensively studied in patients with multidrug …